Stock Analiz

Jaguar Health, Inc. JAGX

Biotechnology: Pharmaceutical Preparations · IPO 2015 · data as of November 13, 2026

$0.42Market cap $6M
Open the interactive analysis →

Jaguar Health, Inc. (JAGX) is a healthcare company listed in the US with a market value of about $6M. In the twelve months to June 30, 2026 it had revenue of $28M and net income of -$52M, a net margin of -188.5%.

Its overall Stock Analiz score is 0.6 out of 5 (weak). The strongest part is future growth (1/5); the weakest is value (0/5).

Key numbers: 5-year revenue growth of 4% a year, a 5-year average ROIC of -108%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 59% below the current price.

About Jaguar Health

Jaguar Health is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2015. Revenue went from $258381 in 2015 to $12M in 2025, growth of about 46.2% a year. It was profitable in 0 of the last 10 years in our data. Its share count rose by 265932% over three years (dilution for shareholders). It spends 217% of revenue on research and development.

Score: 0.6 / 5

Value0/5
Future growth1/5
Track record1/5
Financial health0/5
Shareholder returns1/5

Checks passed

  • Strong R&D investment or growth above 20%
  • ROE above 15%
  • Stock-based pay below 5% of revenue

Checks not passed

  • P/E below 25
  • P/E below the industry median
  • P/FCF below 20
  • Price below intrinsic value (DCF, moderate assumptions)
  • PEG below 1.5
  • Revenue growth above 10% last year
  • 3-year revenue growth above 10% a year
  • Profit margin improving

Valuation

P/E (TTM)—
Forward P/E—
P/FCF—
P/S0.2
P/B1.1
EV/EBITDA—
PEG—
Dividend yield0.00%
FCF yield—
Shareholder yield0.0%
Intrinsic value vs. price−59%

Growth and quality

Revenue growth (1 yr)-1.5%
Revenue growth (5 yrs, per year)4.2%
EPS growth (5 yrs, per year)—
FCF growth (3 yrs, per year)—
Net margin (5-yr avg.)-159.3%
ROIC (5-yr avg.)-107.8%
Profitable years (of last 10)0
Years paying a dividend—

Financials, last 10 years

Fiscal yearTTM2025202420232022202120202019201820172016
Revenue$28M$12M$12M$10M$12M$4M$9M$6M$4M$4M$141523
Net income-$52M-$54M-$38M-$41900-$48400-$52600-$34M-$39M-$32M-$22M-$15M
Free cash flow——-$29M—-$33M-$35M-$15M—-$23M—-$15M
EPS (diluted)$-35.94$-22.97$-130.69$-2678.17$-54122.01$-131969.15$-336579.96$-1010861.82$-17195870.23$-59608368.02$-159034157.84
Net margin-188.5%-465.4%-329.3%-0.4%-0.4%-1.2%-360.2%-667.3%-727.9%-503.7%-10410.9%
ROIC—-184.2%-71.7%-81.7%-102.8%-98.8%-79.8%-125.4%-146.5%-69.2%-836.5%

From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.

Frequently asked questions

Is Jaguar Health stock undervalued?

Our DCF model with moderate assumptions puts its intrinsic value about 59% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.

Does Jaguar Health pay a dividend?

Not currently.

Is Jaguar Health a good stock to buy?

We do not give buy or sell advice. Jaguar Health scores 0.6 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.

Similar companies

Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.